Pediatric Obesity Treatments Surge in United States
Prescriptions for GLP-1 weight loss drugs have increased 310% for adolescents as families seek new medical options.
Updated on Oct. 21, 2026 in Weight Loss
Live Poll
Do you trust the long-term safety of using GLP-1 drugs for children and teens?
As U.S. pediatric obesity rates reach 20%, more adolescents are turning to the GLP-1 medication Wegovy for weight management. Data shows a 310% increase in pediatric prescriptions for the drug between 2019 and 2026.
Why it matters
Managing obesity in children is critical for reducing long-term health risks like high blood pressure, yet clinical approaches are evolving rapidly. This trend highlights the growing reliance on medical interventions alongside lifestyle changes for adolescent patients who struggle to make progress through diet and exercise alone.
Nationwide prescription data indicates a 310% increase in pediatric Wegovy usage from 2019 to 2026, a period where approximately 20% of U.S. children were classified as obese. Researchers are currently investigating the long-term effects of GLP-1 medication use in younger populations.
The players
Wegovy
A weekly GLP-1 receptor agonist medication indicated for weight management.
Hassenfeld Children's Hospital at NYU Langone
A medical center hosting an Adolescent Healthy Weight Program.
The details
Wegovy is the only weekly GLP-1 medication currently approved by the FDA for obesity in children over the age of 12. The medication is typically prescribed by pediatric endocrinologists as part of a comprehensive weight management plan that includes regular exercise and healthy nutrition. In clinical practice, the drug is used to address underlying health risks, such as high blood pressure, when conventional lifestyle interventions have not yielded sufficient clinical progress.
Timeline
2019-2026: Pediatric Wegovy prescriptions rose by 310%.
Past two years: Patient experienced significant BMI reduction and increased physical activity.
October 20, 2026: Date of reporting.
Health Landscape
The current uptick in prescription volume follows the FDA approval of Wegovy for adolescents over 12, marking a shift in standard pediatric weight management. This trend reflects an evolving approach to childhood obesity that increasingly integrates pharmacotherapy with traditional lifestyle interventions.
If your child is struggling with obesity and related health markers like blood pressure, discuss the range of available treatment options with a pediatrician. This conversation should focus on whether a comprehensive weight management program is appropriate and how it would integrate with daily lifestyle habits.
The takeaway
Obesity treatment for adolescents now frequently includes medical support alongside diet and exercise to mitigate long-term health risks. Consult with a pediatric endocrinologist to determine if clinical weight management strategies are a safe and necessary step for your child's specific health profile.
Further reading
Learn more about the latest developments in weight management at the Weight Loss section.
Source note: This article includes information reported by ABC News.
Live Poll
Do you trust the long-term safety of using GLP-1 drugs for children and teens?
